<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> is usually diagnosed by the endoscopic and histological finding of columnar epithelium with <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> in the distal esophagus </plain></SENT>
<SENT sid="1" pm="."><plain>The prevalence of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (long segment) is &lt;2% in the general population and 3-5% in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> reflux symptoms </plain></SENT>
<SENT sid="2" pm="."><plain>Barrett mucosa predisposes patients to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> that develops in approximately 0.5% of these patients per year (Barrett mucosa --&gt; <z:mpath ids='MPATH_589'>dysplasia</z:mpath> --&gt; <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> sequence) </plain></SENT>
<SENT sid="3" pm="."><plain>The incidence of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> over the past few decades; the present incidence, however, is still rather low and is reported to be approximately 4 and approximately 0.5 per 100,000 in males and females, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The malignant potential of the Barrett mucosa increases with dysplastic changes </plain></SENT>
<SENT sid="5" pm="."><plain>Guidelines for surveillance and therapy are based on the presence and the degree of dysplastic lesions </plain></SENT>
<SENT sid="6" pm="."><plain>Long-term studies on cost-effectiveness of these guidelines are, however, still missing </plain></SENT>
</text></document>